A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.
about
Redox-directed cancer therapeutics: molecular mechanisms and opportunitiesDarinaparsin is a multivalent chemotherapeutic which induces incomplete stress response with disruption of microtubules and Shh signalingThe novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cellsFactors determining sensitivity and resistance of tumor cells to arsenic trioxideDimethylarsinothioyl glutathione as a metabolite in human multiple myeloma cell lines upon exposure to DarinaparsinGlutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanismsGlutathione S-conjugates as prodrugs to target drug-resistant tumors.The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis.Darinaparsin: a novel organic arsenical with promising anticancer activity.Role of arsenic trioxide in acute promyelocytic leukemia.Targeting PKC delta-mediated topoisomerase II beta overexpression subverts the differentiation block in a retinoic acid-resistant APL cell line.Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.Multidrug resistance protein 1 (ABCC1) confers resistance to arsenic compounds in human myeloid leukemic HL-60 cells.
P2860
Q24645584-385E8992-0B6C-4C30-A7E5-3420244521DCQ27312382-4D9B456E-36CC-4B37-BB73-99A67964AA14Q28285958-2E75FBF1-2E1C-469C-BA7B-CF291D3BAA9CQ28483625-D7130E66-3F58-4E8E-9475-2A320D4AF4EFQ33637102-31AA7013-6AE0-45F0-8E4F-7BDCECF3830BQ34020461-05DA4EB4-DB5C-4708-9F01-23B0AA01D1D2Q34024771-8BDE8A89-347C-4527-9123-40B520B26564Q34802502-749702CC-3EAA-4D46-A2FA-CB1253247784Q36040432-365C58B8-3D85-4D58-89A6-764B3C5E7EA8Q37603342-24791896-E7BC-4BC2-A322-238D3F27CBB5Q39484903-5E652772-18F8-4286-B30E-6B4233F239BDQ39732586-7487B76B-EDF0-4572-BE67-3F66F91997CEQ39856387-4CACAFD4-681D-4A9C-819F-DD61BC3BB3F7Q41069547-687D8033-4E31-4F58-B6AF-8BB236B3B28DQ42715412-2A2DAC18-5B46-45C8-939A-96A2CE19532F
P2860
A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
A novel arsenical has antitumo ...... CC1-overexpressing cell lines.
@en
A novel arsenical has antitumo ...... CC1-overexpressing cell lines.
@nl
type
label
A novel arsenical has antitumo ...... CC1-overexpressing cell lines.
@en
A novel arsenical has antitumo ...... CC1-overexpressing cell lines.
@nl
prefLabel
A novel arsenical has antitumo ...... CC1-overexpressing cell lines.
@en
A novel arsenical has antitumo ...... CC1-overexpressing cell lines.
@nl
P2093
P2860
P356
P1433
P1476
A novel arsenical has antitumo ...... CC1-overexpressing cell lines.
@en
P2093
M Kourelis
P B Komarnitsky
W H Miller
P2860
P2888
P304
P356
10.1038/LEU.2008.194
P577
2008-07-17T00:00:00Z